NCT02989584

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the safety of the study drug, atezolizumab, when combined with the standard chemotherapy drugs, gemcitabine and cisplatin (or GC). This study will help researchers begin to understand whether combining GC with atezolizumab is better, the same, or worse than the usual approach of using GC alone.

Conditions

• Bladder Cancer
• Metastatic Bladder Cancer
• Urothelial Carcinoma

Interventions

Type	Name	Description
DRUG	Atezolizumab
DRUG	Gemcitabine
DRUG	Cisplatin

Timeline

• Start date: 2016-12-20
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2016-12-12
• Last updated: 2026-01-07

Locations

11 sites across 1 country: United States

Regulatory

• FDA-regulated drug study